Employees
123
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
finch therapeutics is unlocking the therapeutic potential of the microbiome through our human-first discovery platform. we use machine learning algorithms to reverse engineer successful fecal transplantations and other clinical datasets, identifying the microbes that drive responses in patients. this human-centric discovery model leverages clinical data to focus our in-vitro and in-vivo efforts on cocktails of microbes that have already demonstrated safety and efficacy in humans. this enables early retirement of translational risk and avoids the challenges of extrapolating host-specific effects from animal models. our team values transparency, integrity, humility, and collaboration, and we intend to have fun while maximizing our ability to make an impact on patients’ lives.
Loading...
Open
11.50
Mkt cap
19M
Volume
1.2K
High
12.05
P/E Ratio
-1.37
52-wk high
14.26
Low
11.50
Div yield
N/A
52-wk low
0.80
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 3:24 pm
Portfolio Pulse from Avi Kapoor
April 24, 2024 | 5:57 pm
Portfolio Pulse from Avi Kapoor
April 17, 2024 | 5:36 pm
Portfolio Pulse from Benzinga Insights
April 17, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
April 12, 2024 | 8:31 pm
Portfolio Pulse from Happy Mohamed
March 25, 2024 | 9:48 pm
Portfolio Pulse from Avi Kapoor
March 12, 2024 | 6:07 pm
Portfolio Pulse from Benzinga Insights
March 12, 2024 | 1:06 pm
Portfolio Pulse from Avi Kapoor
March 12, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
November 08, 2023 | 11:35 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.